[HTML][HTML] Implications of oncology trial design and uncertainties in efficacy-safety data on health technology assessments
D Trapani, K Tay-Teo, ME Tesch, F Roitberg… - Current …, 2022 - mdpi.com
Background: Advances in cancer medicines have resulted in tangible health impacts, but the
magnitude of benefits of approved cancer medicines could vary greatly. Health Technology …
magnitude of benefits of approved cancer medicines could vary greatly. Health Technology …
Evolution of the joint International Atomic Energy Agency (IAEA), International Agency for Research on Cancer (IARC), and WHO cancer control assessments …
I Veljkovikj, AM Ilbawi, F Roitberg, S Luciani… - The Lancet …, 2022 - thelancet.com
Before 2005, cancer and other non-communicable diseases were not yet health and
development agenda priorities. Since the 2005 World Health Assembly Resolution, which …
development agenda priorities. Since the 2005 World Health Assembly Resolution, which …
[HTML][HTML] Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy …
Objectives Guidelines and essential medicine lists (EMLs) bear similarities and differences
in the process that lead to decisions. Access to essential medicines is central to achieve …
in the process that lead to decisions. Access to essential medicines is central to achieve …
Multicomponent processes to identify and prioritise low-value care in hospital settings: a scoping review
Objectives This scoping review mapped and synthesised original research that identified
low-value care in hospital settings as part of multicomponent processes. Design Scoping …
low-value care in hospital settings as part of multicomponent processes. Design Scoping …
[HTML][HTML] GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists
Objectives Guidelines and essential medicine lists (EMLs) bear similarities and differences
in the process that lead to decisions. Access to essential medicines is central to achieve …
in the process that lead to decisions. Access to essential medicines is central to achieve …
[HTML][HTML] Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1. 1) for adjuvant radiotherapy in breast cancer
Background The European Society of Medical Oncology (ESMO) has suggested using the
ESMO-Magnitude of Clinical Benefit Scale (MCBS) to grade the magnitude of clinical benefit …
ESMO-Magnitude of Clinical Benefit Scale (MCBS) to grade the magnitude of clinical benefit …
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS: H) version 1.0
Background The European Society for Medical Oncology (ESMO)-Magnitude of Clinical
Benefit Scale (MCBS) has been accepted as a robust tool to evaluate the magnitude of …
Benefit Scale (MCBS) has been accepted as a robust tool to evaluate the magnitude of …
[HTML][HTML] Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
Background Cancer is a global public health problem, requiring efficient health system
investments to deliver sustainable impact on population health. Access to medicines is a …
investments to deliver sustainable impact on population health. Access to medicines is a …
[HTML][HTML] WHO-ESMO collaboration in cancer control: policies into action to save lives
B Mikkelsen, S Peters - ESMO open, 2022 - esmoopen.com
There is now unique political and social momentum to prioritise health and well-being,
accentuated by the crises wrought by the COVID-19 pandemic. We have the opportunity to …
accentuated by the crises wrought by the COVID-19 pandemic. We have the opportunity to …
Is the Juice Worth the Squeeze? Overall Survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
N Joseph, V Bamunuarachchi, V Peiris, S Wijeskera… - medRxiv, 2023 - medrxiv.org
Introduction Novel systemic therapeutic options such as enzyme inhibitors and monoclonal
antibodies have transformed the practice of medical oncology in the recent past. However …
antibodies have transformed the practice of medical oncology in the recent past. However …